Molecular Imaging and Biology

, Volume 18, Issue 4, pp 479–482 | Cite as

Human Radiation Dosimetry of [18F]AV-1451(T807) to Detect Tau Pathology

  • Jae Yong Choi
  • Chul Hyoung Lyoo
  • Jae Hoon Lee
  • Hanna Cho
  • Kyeong Min Kim
  • Jin Su Kim
  • Young Hoon Ryu
Brief Article



[18F]AV-1451 is a positron emission tomography (PET) radioligand for detecting paired helical filament tau. Our aim was to estimate the radiation dose of [18F]AV-1451 in humans.


Whole-body PET scans were acquired for six healthy volunteers (three male, three female) for 128 min after injection of [18F]AV-1451 (268 ± 31 MBq). Radiation doses were estimated using the OLINDA/EXM software.


The estimated organ doses ranged from 7.81 to 81.2 μSv/MBq. The critical organ for radiation burden was the liver. Radiation doses to the reproductive and blood-forming organs were 14.15, 8.43, and 18.35 μSv/MBq for the ovaries, testes, and red marrow, respectively. The mean effective dose was 22.47 ± 3.59 μSv/MBq.


A standard single injection of 185 MBq (5 mCi) results in an effective dose of 4.7 mSv in a healthy subject. Therefore, [18F]AV-1451 could be used in multiple PET scans of the same subject per year.

Key words

Tau PET Dosimetry [18F]AV-1451 



This research was supported by the Nuclear R&D Program of the National Research Foundation of Korea (Grant No. NRF-2015M2A2A7027110) and the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIP) (No. 2015R1C1A2A01054507). The authors express gratitude to Tae Ho Sung, Won Tak Lee and Min Soo Jeon who managed all PET scans.

Compliance with Ethical Standards

Conflict of Interest

The authors declare that they have no conflicts of interest.

Ethical Approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.


  1. 1.
    Buee L, Bussiere T, Buee-Scherrer V et al (2000) Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res Brain Res Rev 33:95–130CrossRefPubMedGoogle Scholar
  2. 2.
    Dani M, Edison P, Brooks DJ (2015) Imaging biomarkers in tauopathies. Parkinsonism Relat Disord 22:S26–S28CrossRefPubMedGoogle Scholar
  3. 3.
    Chien DT, Szardenings AK, Bahri S et al (2014) Early clinical PET imaging results with the novel PHF-tau radioligand [F18]-T808. J Alzheimers Dis 38:171–184PubMedGoogle Scholar
  4. 4.
    Harada R, Okamura N, Furumoto S et al (2015) [18F]THK-5117 PET for assessing neurofibrillary pathology in Alzheimer’s disease. Eur J Nucl Med Mol Imaging 42:1052–1061CrossRefPubMedGoogle Scholar
  5. 5.
    Harada R, Okamura N, Furumoto S et al (2013) Comparison of the binding characteristics of [18F]THK-523 and other amyloid imaging tracers to Alzheimer’s disease pathology. Eur J Nucl Med Mol Imaging 40:125–132CrossRefPubMedGoogle Scholar
  6. 6.
    Tago T, Furumoto S, Okamura N, et al. (2015) Preclinical evaluation of [18F]THK-5105 enantiomers: effects of chirality on its effectiveness as a tau imaging radiotracer. Mol Imaging BiolGoogle Scholar
  7. 7.
    Zimmer ER, Leuzy A, Gauthier S, Rosa-Neto P (2014) Developments in tau PET imaging. Can J Neurol Sci 41:547–553CrossRefPubMedGoogle Scholar
  8. 8.
    Chien DT, Bahri S, Szardenings AK et al (2013) Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807. J Alzheimers Dis 34:457–468PubMedGoogle Scholar
  9. 9.
    Marquie M, Normandin MD, Vanderburg CR et al (2015) Validating novel tau positron emission tomography tracer [F-18]-AV-1451 (T807) on postmortem brain tissue. Ann Neurol 78:787–800CrossRefPubMedGoogle Scholar
  10. 10.
    Maruyama M, Shimada H, Suhara T et al (2013) Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls. Neuron 79:1094–1108CrossRefPubMedGoogle Scholar
  11. 11.
    Xia CF, Arteaga J, Chen G et al (2013) [18F]T807, a novel tau positron emission tomography imaging agent for Alzheimer’s disease. Alzheimers Dement 9:666–676CrossRefPubMedGoogle Scholar
  12. 12.
    Shoup TM, Yokell DL, Rice PA et al (2013) A concise radiosynthesis of the tau radiopharmaceutical, [18F]T807. J Labelled Comp Radiopharm 56:736–740CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Hines CS, Liow JS, Zanotti-Fregonara P et al (2011) Human biodistribution and dosimetry of 11C-CUMI-101, an agonist radioligand for serotonin-1a receptors in brain. PLoS One 6:e25309CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Zanotti-Fregonara P, Lammertsma AA, Innis RB (2013) Suggested pathway to assess radiation safety of 18F-labeled PET tracers for first-in-human studies. Eur J Nucl Med Mol Imaging 40:1781–1783CrossRefPubMedGoogle Scholar
  15. 15.
    International Commission on Radiological Protection (1996) Radiological Protection and Safety in Medicine. OxfordGoogle Scholar

Copyright information

© World Molecular Imaging Society 2015

Authors and Affiliations

  • Jae Yong Choi
    • 1
  • Chul Hyoung Lyoo
    • 2
  • Jae Hoon Lee
    • 1
  • Hanna Cho
    • 2
  • Kyeong Min Kim
    • 3
  • Jin Su Kim
    • 3
  • Young Hoon Ryu
    • 1
  1. 1.Department of Nuclear Medicine, Gangnam Severance HospitalYonsei University College of MedicineSeoulSouth Korea
  2. 2.Department of Neurology, Gangnam Severance HospitalYonsei University College of MedicineSeoulSouth Korea
  3. 3.Molecular Imaging Research CenterKorea Institute of Radiological and Medical SciencesSeoulSouth Korea

Personalised recommendations